Biosortia Microbiomics directly obtains previously impossible but highly sought after small-molecules from microbes for new drug therapies. Biosortia’s massive scale processing will drive a rapidly expanding intellectual property and data portfolio resulting in an ever-growing pipeline of opportunities for sales, licensing, and services for high-value customers.

Obtaining the drug-like chemistry of microorganisms has been incredibly problematic and difficult with less than 1% of microbes available for direct exploration of the microbiome’s hidden and elusive chemistry. Despite the limitations, the 1% access has been one of the most successful sources to find valuable starting points in therapeutics, agrochemical, and other life science opportunities.